NovaBay Pharmaceuticals, Inc.
4.99%
6,388,000
1389545
66987P409
Oct 20, 2025
Jan 29, 2026, 07:38 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| David E. Lazar | Individual | 4.99% | 6,388,000 | 6,388,000 | 0 |
Disclosure Items (3)
Common Stock, $0.01 par value
NovaBay Pharmaceuticals, Inc.
2000 POWELL STREET, SUITE 1150, Emeryville, CA, 94608
The aggregate percentage of Shares owned by the Reporting Person is based upon 127,894,134 shares of Common Stock outstanding as of January 29, 2026 based upon information provided by the Issuer. As of the close of business on January 29, 2026, the Reporting Person beneficially owned 6,388,000 Shares. Percentage: Approximately 4.99%
1. Sole power to vote or direct vote: 6,388,000 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 6,388,000 4. Shared power to dispose or direct the disposition: 0
The transactions in the Shares by the Reporting Person during the past sixty days are set forth in more detail in Item 6.
No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
Not applicable.
Item 6 is hereby amended to add the following: At the Annual Meeting, the Issuer's stockholders approved, among other things, the conversion of Series D Preferred Stock into shares of common stock ("Stockholder Approval"). Three business days following such Stockholder Approval, all of the Reporting Person's Series D Preferred Stock was automatically converted into shares of the Issuer's Common Stock.